SAB-185

BIOLOGICAL2 trials

Sponsors

SAb Biotherapeutics, Inc.

Conditions

COVID-19SARS-CoV2

Phase 1

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

SAb Biotherapeutics, Inc.COVID-19, SARS-CoV2

Start: 2020-08-20End: 2021-11-30Updated: 2021-10-26

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

CompletedNCT04468958

SAb Biotherapeutics, Inc.COVID-19, SARS-CoV2

Start: 2020-07-01End: 2020-12-23Updated: 2022-07-01

Related Papers

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants

Frontiers in Immunology2021-11-1512 citations